After record-breaking years in 2020 and 2021, biotech private fundraising in 2023 returned to pre-pandemic levels, while the amounts raised through initial public offerings was the lowest since 2013. With the cost of developing clinical assets continuing to rise, biotechs with preclinical assets are finding it harder to raise the capital needed to advance their candidate medicines. In this webinar biotech and financing executives spoke with Mike Ward of Clarivate on the current biotech financing landscape and tactics and strategies companies might need to consider as they navigate this challenging environment. Featuring Claus Kremoser, founder and CEO of WMT, and Jack Hoppin, co-founder, chairman and CEO of Ratio Therapeutics, together with venture investor Stephan Christgau, founding partner at Eir Ventures.
This webinar will answer questions such as:
- What are the issues keeping biophama execs awake at night in 2024?
- What could trigger a resumption of large-scale investment? What’s the sweet spot for investors?
- How can small biotechs, particularly those lacking founders with a track record of building companies, secure share of voice and attract investors?
- What’s the ideal mix of investment for biotechs between venture capital, strategic investments and family funds, etc.?
- Where are the potential green shoots in the financing environments for biotechs?